Medtech startup See-Mode gets Canada's nod for AI breast, thyroid ultrasound analysis software
Its technology helps eliminate manual steps in reporting and interpretation of ultrasound images of breast and thyroid.
Stay updated with breaking news from Medo Thyroid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Its technology helps eliminate manual steps in reporting and interpretation of ultrasound images of breast and thyroid.
Exo said integrating Medo's AI tools into its platform will let healthcare workers with less ultrasound expertise capture and interpret images.
Exo acquires Medo, a an FDA-cleared AI platform that makes ultrasound workflow faster, more reliable, and accessible to all.
Kailo Medical, a healthcare technology company with products that streamline structured reporting in the hospital setting, today announces its integration with Medo, an Artificial Intelligence company dual-headquartered in Singapore and Edmonton. The integration will see Medo Thyroid integrated into Kailo's SonoReview product to make nodule classification quicker, simpler and more accurate, ultimately leading to better outcomes for patients.